{"id":32898,"date":"2025-05-06T16:47:12","date_gmt":"2025-05-06T08:47:12","guid":{"rendered":"https:\/\/flcube.com\/?p=32898"},"modified":"2025-05-06T16:47:14","modified_gmt":"2025-05-06T08:47:14","slug":"guilin-sanjins-bc006-monoclonal-antibody-gains-nmpa-approval-for-ipf-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32898","title":{"rendered":"Guilin Sanjin&#8217;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials"},"content":{"rendered":"\n<p>Guilin Sanjin Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/002275:SHE\">SHE: 002275<\/a>) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical&#8217;s BC006 monoclonal antibody (mAb) for injection has obtained another clinical approval from the National Medical Products Administration (NMPA). The drug, touted as the first domestically developed colony-stimulating factor 1 receptor (CSF-1R) antibody to enter clinical trials in China, will now be evaluated for idiopathic pulmonary fibrosis (IPF).<\/p>\n\n\n\n<p><strong>BC006 Development and Indications<\/strong><br>BC006 is a humanized IgG1 mAb targeting macrophage CSF-1R and is under development for advanced malignancies, hematologic tumors, and bone\/joint disorders. The drug initially secured Chinese clinical trial authorization in March 2021. This latest approval expands its clinical evaluation into IPF, a progressive lung disease with significant unmet medical needs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/\u6842\u6797\u4e09\u91d1\uff1a\u5173\u4e8e\u63a7\u80a1\u5b59\u516c\u53f8BC006\u5355\u6297\u6ce8\u5c04\u6db2\u65b0\u589e\u9002\u5e94\u75c7\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Guilin Sanjin&apos;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials.\"><\/object><a id=\"wp-block-file--media-32d330e9-5f26-42b3-8153-9670c55881e8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/\u6842\u6797\u4e09\u91d1\uff1a\u5173\u4e8e\u63a7\u80a1\u5b59\u516c\u53f8BC006\u5355\u6297\u6ce8\u5c04\u6db2\u65b0\u589e\u9002\u5e94\u75c7\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u7684\u516c\u544a.pdf\">Guilin Sanjin&#8217;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/\u6842\u6797\u4e09\u91d1\uff1a\u5173\u4e8e\u63a7\u80a1\u5b59\u516c\u53f8BC006\u5355\u6297\u6ce8\u5c04\u6db2\u65b0\u589e\u9002\u5e94\u75c7\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-32d330e9-5f26-42b3-8153-9670c55881e8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32902,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,3660,336,1169],"class_list":["post-32898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-dragon-boat-biopharmaceutical","tag-sanjin-pharmaceutical","tag-she-002275"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Guilin Sanjin&#039;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical&#039;s BC006 monoclonal antibody (mAb) for injection has obtained another clinical approval from the National Medical Products Administration (NMPA). The drug, touted as the first domestically developed colony-stimulating factor 1 receptor (CSF-1R) antibody to enter clinical trials in China, will now be evaluated for idiopathic pulmonary fibrosis (IPF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32898\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guilin Sanjin&#039;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials\" \/>\n<meta property=\"og:description\" content=\"Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical&#039;s BC006 monoclonal antibody (mAb) for injection has obtained another clinical approval from the National Medical Products Administration (NMPA). The drug, touted as the first domestically developed colony-stimulating factor 1 receptor (CSF-1R) antibody to enter clinical trials in China, will now be evaluated for idiopathic pulmonary fibrosis (IPF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32898\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-06T08:47:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T08:47:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0513.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Guilin Sanjin&#8217;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials\",\"datePublished\":\"2025-05-06T08:47:12+00:00\",\"dateModified\":\"2025-05-06T08:47:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898\"},\"wordCount\":146,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0513.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Dragon Boat Biopharmaceutical\",\"Sanjin Pharmaceutical\",\"SHE: 002275\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32898#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32898\",\"name\":\"Guilin Sanjin's BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0513.webp\",\"datePublished\":\"2025-05-06T08:47:12+00:00\",\"dateModified\":\"2025-05-06T08:47:14+00:00\",\"description\":\"Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical's BC006 monoclonal antibody (mAb) for injection has obtained another clinical approval from the National Medical Products Administration (NMPA). The drug, touted as the first domestically developed colony-stimulating factor 1 receptor (CSF-1R) antibody to enter clinical trials in China, will now be evaluated for idiopathic pulmonary fibrosis (IPF).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32898\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0513.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0513.webp\",\"width\":1080,\"height\":608,\"caption\":\"Guilin Sanjin's BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32898#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guilin Sanjin&#8217;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guilin Sanjin's BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical's BC006 monoclonal antibody (mAb) for injection has obtained another clinical approval from the National Medical Products Administration (NMPA). The drug, touted as the first domestically developed colony-stimulating factor 1 receptor (CSF-1R) antibody to enter clinical trials in China, will now be evaluated for idiopathic pulmonary fibrosis (IPF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32898","og_locale":"en_US","og_type":"article","og_title":"Guilin Sanjin's BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials","og_description":"Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical's BC006 monoclonal antibody (mAb) for injection has obtained another clinical approval from the National Medical Products Administration (NMPA). The drug, touted as the first domestically developed colony-stimulating factor 1 receptor (CSF-1R) antibody to enter clinical trials in China, will now be evaluated for idiopathic pulmonary fibrosis (IPF).","og_url":"https:\/\/flcube.com\/?p=32898","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-06T08:47:12+00:00","article_modified_time":"2025-05-06T08:47:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0513.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32898#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32898"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Guilin Sanjin&#8217;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials","datePublished":"2025-05-06T08:47:12+00:00","dateModified":"2025-05-06T08:47:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32898"},"wordCount":146,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32898#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0513.webp","keywords":["Clinical trial approval \/ initiation","Dragon Boat Biopharmaceutical","Sanjin Pharmaceutical","SHE: 002275"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32898#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32898","url":"https:\/\/flcube.com\/?p=32898","name":"Guilin Sanjin's BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32898#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32898#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0513.webp","datePublished":"2025-05-06T08:47:12+00:00","dateModified":"2025-05-06T08:47:14+00:00","description":"Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical's BC006 monoclonal antibody (mAb) for injection has obtained another clinical approval from the National Medical Products Administration (NMPA). The drug, touted as the first domestically developed colony-stimulating factor 1 receptor (CSF-1R) antibody to enter clinical trials in China, will now be evaluated for idiopathic pulmonary fibrosis (IPF).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32898#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32898"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32898#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0513.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0513.webp","width":1080,"height":608,"caption":"Guilin Sanjin's BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32898#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Guilin Sanjin&#8217;s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0513.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32898"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32898\/revisions"}],"predecessor-version":[{"id":32904,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32898\/revisions\/32904"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32902"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}